Award type :
Product Development Award
Product Development Award
Product type :
Vaccines
Vaccines
Award year :
2022
2022
Project start date :
04 / 11 / 2022
04 / 11 / 2022
Project end date :
06 / 30 / 2023
06 / 30 / 2023
Project duration (months) :
12
12
Development stage :
Preclinical
Preclinical
Target disease :
COVID-19
COVID-19
Region served :
Low- and Middle-Income Countries
Low- and Middle-Income Countries
Recipient organization / Country of funding recipient organization :
CHA Vaccine Institute / Republic of Korea
CHA Vaccine Institute / Republic of Korea
Collaborator(s) / Country :
BioLingus / Switzerland
BioLingus / Switzerland
Funding amount(KRW) :
500,000,000
500,000,000
This project aims to develop a sublingual delta variant RBD-dimer protein subunit COVID-19 vaccine in combination with a proprietary adjuvant, L-pampo™. In addition to ease of administration, the sublingual vaccine promises enhanced thermostability and storage capacity at room temperature, thereby reducing distribution costs and addressing barriers in vaccine accessibility. Stages funded through this project include vaccine formulation and immunogenicity and efficacy studies in animal models. This novel vaccine platform has potential implications beyond COVID-19, and its successful development will contribute to overcoming vaccine inequity across broad categories of vaccines.